Methocarbamol and Simponi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methocarbamol (methocarbamol) and Simponi (golimumab). Common drug interactions include obstruction among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Methocarbamol and Simponi. It is created by eHealthMe based on reports of 38 people who take the same drugs from the FDA, and is updated regularly.

What is Methocarbamol?

Methocarbamol has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 17,766 Methocarbamol users. Check the latest studies of Methocarbamol.

What is Simponi?

Simponi has active ingredients of golimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 86,328 Simponi users. Check the latest studies of Simponi.



On Jul, 27, 2026

38 people who take Methocarbamol and Simponi together, and have interactions are studied.

Methocarbamol and Simponi drug interactions.

What are the common drug interactions of Methocarbamol and Simponi, by gender? *:

female:

  1. Obstruction
  2. Abscess (pus)
  3. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)
  4. Diarrhoea
  5. Nausea (feeling of having an urge to vomit)
  6. Peripheral swelling
  7. Psoriasis (immune-mediated disease that affects the skin)
  8. Psoriatic arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop)
  9. Staphylococcal infection (an infection with staphylococcus bacteria)
  10. Allergy to animal

male:

  1. Drug ineffective
  2. Synovitis (inflammation of the synovial membrane)
  3. Body temperature increased
  4. Drug effect decreased
  5. Influenza
  6. Lethargy (tiredness)
  7. Pruritus (severe itching of the skin)

What are the common drug interactions of Methocarbamol and Simponi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Diarrhoea
  2. Dyspepsia (indigestion)
  3. Migraine (headache)
  4. Nausea (feeling of having an urge to vomit)
  5. Pruritus (severe itching of the skin)
  6. Vomiting

40-49:

  1. Anaphylactic reaction (serious allergic reaction)
  2. Body temperature increased
  3. Dyspnoea (difficult or laboured respiration)
  4. Fatigue (feeling of tiredness)
  5. Influenza
  6. Lethargy (tiredness)
  7. Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
  8. Peripheral swelling
  9. Psoriasis (immune-mediated disease that affects the skin)
  10. Psoriatic arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop)

50-59:

  1. Surgery
  2. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)
  3. Fatigue (feeling of tiredness)
  4. Heart rate decreased
  5. Hypotension (abnormally low blood pressure)

60+:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Limb injury
  3. Hospitalisation
  4. Memory impairment
  5. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  6. Pneumonia
  7. Pyrexia (fever)
  8. Synovitis (inflammation of the synovial membrane)
  9. Weight decreased
  10. Arthritis (form of joint disorder that involves inflammation of one or more joints)

What are the existing conditions these people have? *

  1. Ankylosing Spondylitis (type of arthritis affecting the spine): 7 people, 18.42%
  2. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 4 people, 10.53%
  3. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 10.53%
  4. Multiple Myeloma (cancer of the plasma cells): 3 people, 7.89%
  5. Inflammation: 3 people, 7.89%
  6. Indigestion: 3 people, 7.89%
  7. Pustular Psoriasis (raised bumps on the skin that are filled with pus): 2 people, 5.26%
  8. Psoriasis (immune-mediated disease that affects the skin): 2 people, 5.26%
  9. Pain: 2 people, 5.26%
  10. High Blood Pressure: 2 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Methocarbamol and Simponi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methocarbamol and Simponi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methocarbamol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Simponi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methocarbamol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Simponi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol and golimumab (the active ingredients of Methocarbamol and Simponi, respectively), and Methocarbamol and Simponi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: